Functional in vitro and in vivo preclinical models of melanoma initially demonstrated the utility of small molecule BRAF inhibitors for the treatment of BRAF-mutant melanoma, providing the scientific rationale for BRAF inhibitor clinical trials18,19. This evidence concerns the gene BRAF and melanoma.